WWM
ALNY icon

Western Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Western Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,838
Closed -$300K – 789
2022
Q1 		$300K Buy
+1,838
New +$280K 0.01% 676

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Western Wealth Management's ALNY Position: Q2 2022 in Review

Western Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 1,838 shares — an estimated $300K sold.

Western Wealth Management first reported a position in ALNY in Q1 2022 and held it in 1 quarter. The position peaked at $300K in Q1 2022. 421 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Western Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Western Wealth Management sold 1,838 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $300K.
  • Western Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Western Wealth Management's Alnylam Pharmaceuticals position peaked at $300K in Q1 2022.
  • 421 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Western Wealth Management's 13F filing for Q2 2022, filed 18 Jul 2022.